Additionally, the limited efficacy of PD(L)-1 inhibitors in ovarian cancer treatment highlights the need for innovative therapeutic approaches and novel targets for patients who are not candidates for surgery or develop resistance to platinum-based neoadjuvant chemotherapy (Fig. 1a). This evidence concerns the gene CD274 and ovarian carcinoma.